INTERLEUKIN 28B GENE POLYMORPHISMS AS A PREDICTOR OF TREATMENT RESPONSE IN EGYPTIANS WITH CHRONIC HEPATITIS C.

ROLE OF SERUM INTERLEUKIN – 10 AND INTERLEUKIN -28B GENE POLYMORPHISMS IN PREDICTING TREATMENT RESPONSE OF HEPATITIS C PATIENTS

Single nucleotide polymorphism (SNP) rs8099917 as a predictive factor of virological response to pegylated interferon plus Ribavirin in treatment of chronic hepatitis c virus patients

Interleukin 28B Polymorphism as a Predictor of Response to Treatment of Egyptian HCV Patients Working in Nuclear Material Authority

Liver Fibrosis as a Predictive Factor of Response to Pegylated-IFN/ Ribavirin Therapy in Chronic HCV Patients

The relation between interleukin 28B gene polymorphisms (rs8099917 and rs12980275) and the response of treatment of Hepatitis C Virus genotype 4 patients to Sofosbuvir and Daclat

Impact of IL28B Polymorphism on the Response to Treatment of Hepatitis C with Interferon Based Therapy or Direct Acting Antivirals

The effect of the polymorphism in IL-28B gene on the treatment response of a combined therapy by sofosbuvir and daclatasvir with and without ribavirin in HCV Egyptian patients

Comparison between clinical and biochemical versus interleukin 28B as a predictive factor of virological response to direct antiviral drugs without interferone in treatment of hep

Study of prediction of response to pegylated interferon plus ribavirin in hepatitis C patients by IL28B gene variation and its relation to other different predictors